Liraglutide and Semaglutide Market - By Type (Pills, Liquid), Route of Administration (Parenteral, Oral) Application (Type 2 Diabetes Mellitus, Obesity), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), & Global Forecast 2023 - 2032

Liraglutide and Semaglutide Market Size

Liraglutide and Semaglutide Market size valued at USD 14.2 billion in 2022 and is estimated to grow at a 11.3% CAGR between 2023 to 2032. Increasing prevalence diabetes coupled with increasing awareness regarding obesity is expected to boost the market growth.
 

Liraglutide and semaglutide are pharmaceutical medications categorized as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). They are used primarily in the treatment of type 2 diabetes and obesity. Liraglutide and semaglutide act by mimicking the effects of the GLP-1 hormone in the body, helping to regulate blood sugar levels, promote weight loss, and reduce the risk of cardiovascular complications.
 

COVID-19 Impact

The COVID-19 pandemic has severely impacted the global economies with all the sectors witnessing a significant slump during 2020. The healthcare sector was one of the most severely impacted sectors during the pandemic owing to tremendous pressure on the healthcare systems to contain the spread of infection. The pandemic has prompted increased attention towards underlying health conditions leading to growing awareness regarding importance of managing chronic diseases such as diabetes and obesity. Thus, growing awareness created significant demand for medications like liraglutide and semaglutide, as individuals strive to improve their overall health and immune system.
 

Additionally, the shift towards telehealth services and remote consultations during the pandemic has facilitated easier access to healthcare professionals and medication prescriptions. Thus, aforementioned factors have contributed to a sustained demand for liraglutide and semaglutide, thereby positively impacting the market growth.
 

Liraglutide and Semaglutide Market Trends

Obesity is one of the major risk factors contributing to the higher prevalence of diabetes, thus propelling the demand for liraglutide and semaglutide. Obesity leads to increased levels of inflammation and fatty acids that result in insulin resistance causing the risk of type 2 diabetes. Thus, increasing obesity rates globally has created significant demand for effective treatments for weight management and related health conditions. Also, positive results in maintaining blood sugar control, blood pressure and cholesterol levels have significantly demonstrated potential therapeutic applications. Thus, increasing awareness regarding diabetes, obesity related health conditions and favourable government initiatives for preventive healthcare is expected to boost the market growth.
 

Liraglutide and Semaglutide Market Restrain

Various side effects associated with liraglutide and semaglutide use for diabetes and obesity treatment may significantly hamper the market growth. Common side effects associated with the use of these medications include nausea, vomiting, diarrhea and stomach pain. Also, semaglutide injection may increase the risk of developing tumors of the thyroid gland, including medullary thyroid carcinoma. They may potentially increases the risk of pancreatitis and in some cases the patient may also experience hypoglycemia and allergic reactions. Thus, various adverse effects associated with the use of liraglutide and semaglutide may significantly hamper the market growth.
 

Liraglutide and Semaglutide Market Analysis

By type, the liraglutide and semaglutide market is classified into pills and liquid. The liquid segment accounted for 78% of the market share in 2022 and is projected to witness robust growth over the analysis timeframe. The liquid form of liraglutide and semaglutide provides convenient administration and potential adherence improvements in patients. Also, the liquid form enables more accurate and precise dosage, ensuring optimal delivery of the medication. This precise dosing capability can contribute to improved glycemic control and may result in a reduced risk of hypoglycemia episodes. Additionally, the liquid form offers a faster onset of action that enables to enhances the patient experience and treatment outcomes, thereby propelling the market statistics.
 

Based on route of administration, the liraglutide and semaglutide market is segmented into parenteral and oral. The parenteral are expected to register around USD 39 billion by end of 2032. Increasing segmental growth is owing to the low frequency offered by the parenteral route of administration as compared to the pills. The subcutaneous injection is administered once a week whereas the tablet is administered once a day.
 

Furthermore, the parenteral route of administration enables bypassing the digestive system that allows liraglutide and semaglutide to be directly absorbed into the bloodstream, resulting in higher bioavailability compared to oral medications. The parenteral route of administration ensures that the amount of the drug reaches its target site and enables to attain therapeutic effects more efficiently. Such aforementioned factors will propel the segmental growth.
 

By application, the liraglutide and semaglutide market is segmented into type 2 diabetes and obesity and others. The type 2 diabetes mellitus segment accounted for significant market revenue in 2022 and is expected to grow at 11.4% during the forecast period. Liraglutide and semaglutide are medications that are commonly used to treat type 2 diabetes mellitus owing to effective control on blood sugar levels by stimulating insulin release and reducing the production of glucagon. Furthermore, the medication enables to attain better glycemic control, reduce the risk of cardiovascular events such as heart attacks and strokes. Thus, various benefits associated with the use of liraglutide and semaglutide drugs in diabetes management is expected to drive the market expansion.
 

The distribution channel in liraglutide and semaglutide market is divided into hospital pharmacies, retail pharmacies, online pharmacies. Hospital pharmacies accounted for USD 7 billion market revenue in 2022. Hospital pharmacies provide a centralized and controlled environment for medication storage and dispensing, ensuring product quality and safety. Also, hospital pharmacies have the expertise to handle specialized medications and skilled professionals that enables to provide seamless coordination of care. Furthermore, hospital pharmacies have established relationships with healthcare providers that ensures efficient prescription processing, timely access to liraglutide and semaglutide and integrated patient care. Thus, the benefits associated with the hospital pharmacies is expected to significantly contribute to the market size.
 

North America liraglutide and semaglutide market accounted for over 71% market share in 2022 and is anticipated to grow at considerable growth rate during the forecast timeframe. The increasing prevalence of diabetes and rising awareness regarding the importance of disease management have contributed to the growing demand for liraglutide and semaglutide in the North America region. Furthermore, favorable reimbursement policies and healthcare infrastructure have facilitated their accessibility of liraglutide and semaglutide. Also, presence of key market players and introduction of advanced formulations is expected to proliferate the market growth in the North America region.
 

Liraglutide and Semaglutide Market Share

Major market players operating in the liraglutide and semaglutide market include

• Novo Nordisk A/S
• HEC Pharma Co
• Shenzhen JYMed Technology Co. Ltd.
• Bachem Holding AG

These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition. Also, kindly note that the company profile section include both companies that have commercial drug available in market as well as those that are into clinical phase development.
 

Liraglutide and Semaglutide Industry News:

• In March 2023, HEC Pharma’s Rongliflozin is under clinical development in Phase I for Type 2 diabetes. This clinical development will help the company to enhance its product offering in liraglutide and semaglutide market and assist in strengthening the market position.
   
• In June 2021, Novo Nordisk announced that the U.S. FDA has approved Wegovy, a weekly once semaglutide 2.4 mg injection in the US. Market. The medication is indicated as an adjunct to diet and exercise for chronic weight management in adults with obesity. This strategy helped the company to enhance its product offerings and strengthen revenue generation stream.
   

This liraglutide and semaglutide market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

By Type

• Pills
• Liquid

Route of Administration

• Parenteral
• Oral

Application

• Type 2 Diabetes mellitus
• Obesity
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA